本研究的目的是探讨血脂症对HBsAg测量的干扰,抗HBs,HBeAg,反HBe,抗HBc,抗HCV,HIVAg/Ab,通过化学发光微粒免疫测定(CMIA)和血清中的抗TP,并比较了高速离心和Lipoclear试剂之间的脂血去除性能。制备混合的天然血清样品(NSs)和高脂血症血清样品(HLS)以用于所研究的参数。NS和HLS中这些参数的水平通过CMIA在AbbottARCHITECTi2000SR免疫测定分析仪上测定。HBsAg,抗HBs,当三酰甘油(TG)水平高于HLS中的27.12mmol/L时,抗TP的相对偏差>12.5%(可接受的极限)。在TG高于40.52mmol/L的HLS中观察到HBeAg和抗HBe的临床上不可接受的偏差。然而,抗HCV和HIVAg/Ab在TG<52.03mmol/L的严重血脂中没有受到干扰。此外,Lipoclear试剂没有降低脂血的干扰,相对偏差从-62.50%降至-18.02%.在12000g的优化条件下高速离心10分钟,成功地消除了血脂症的干扰,对HBsAg的相对偏差从-5.93%到0%,抗HBs,HBeAg,反HBe,抗HBc,和抗TP。最后,高速离心可用于去除脂血的干扰以测量HBsAg,抗HBs,HBeAg,反HBe,抗HBc,和抗TP。因此,建议对患者和其他筛查参与者进行标准化的样品分析前准备,并采用标本检查程序,以消除血脂对血清学检测的干扰.
The aim of this study was to investigate the interference of
lipemia on measurement of HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc, anti-HCV, HIV Ag/Ab, and anti-TP in serum by chemiluminescent microparticle immunoassay (CMIA) and compare
lipemia removing performance between high-speed centrifugation and Lipoclear reagent. Mixed native serum samples (NSs) and hyperlipemia serum samples (HLS) were prepared for the investigated parameters. The levels of these parameters in NS and HLS were determined by CMIA on an Abbott ARCHITECT i2000SR immunoassay analyzer. HBsAg, anti-HBs, and anti-TP were affected with relative bias >12.5% (acceptable limit) when the level of triacylglycerol (TG) was higher than 27.12 mmol/L in HLS. Clinically unacceptable bias were observed for HBeAg and anti-HBe in HLS with TG higher than 40.52 mmol/L. However, anti-HCV and HIV Ag/Ab were not interfered in severe
lipemia with TG < 52.03 mmol/L. In addition, the Lipoclear reagent did not reduce the interference of
lipemia with relative bias from -62.50% to -18.02%. The high-speed centrifugation under the optimized condition of 12 000g for 10 min successfully removed the interference of lipemia with relative bias from -5.93% to 0% for HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc, and anti-TP. To conclude, high-speed centrifugation can be used for removing the interference of
lipemia to measure HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc, and anti-TP. Accordingly, a standardized sample preanalytical preparation of the patients and other screening participants as well as a specimen examination procedure for removing lipemia interference on the serological tests was recommended.